Evaluating Cost Impact From a Hospital Perspective: On-Body Delivery System (OBDS) Versus Manual Syringes for In-Clinic, Large-Volume Subcutaneous Oncology Drug Administration

OBJECTIVES: Large-volume subcutaneous (LVSC) drug development has surged in recent years. While hyaluronidase-formulated subcutaneous (SC) drugs have demonstrated time-and-motion benefits in the clinic setting, an opportunity exists to provide an improved administration experience with additional economic benefits. This hypothesis-generating model evaluates the cost-impact of an On-Body Delivery System (OBDS) for administering LVSC oncology treatments, comparing it against traditional IV and LVSC infusion methods. It is synthesized from the perspective of the hospital system and provides guidance regarding cost-effective oncology drug delivery.

METHODS: A cost-impact model was synthesized to compare the direct and indirect costs of using an OBDS for LVSC oncology treatments versus traditional IV and SC methods. Data inputs were collected from relevant literature, surveys, and databases to estimate the drug costs, HCP burden, and other resources. The model projected these costs per 1000 patients over one year to capture the long-term impact. A sensitivity analyses was also performed to see how changes in treatment frequency or resource use would impact the results.

RESULTS: The model indicated that utilizing an OBDS for oncology treatments in the clinic significantly reduced administration-related costs across all treatment scenarios when compared to both IV infusions and traditional SC infusions. For daratumumab administration, the OBDS demonstrated a savings of $6,520,722. Subcutaneous rituximab, trastuzumab, and trastuzumab/pertuzumab demonstrated a savings of $5,400,878, $5,820,359, and $5,847,359, respectively. When comparing OBDS versus IV, the savings were even greater in most cases with the OBDS.

CONCLUSIONS: While the benefits of OBDSs use for self-administration are evident, its utility in the clinic remains less obvious. This model offers hospitals clear guidance, demonstrating that employing OBDSs in the clinic setting can lead to cost savings and operational efficiencies. Through careful analysis, it becomes evident that OBDS not only reduces direct and indirect healthcare costs but also enhances workflow efficiency, improving the HCP and patient experience.